This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/09/15

    EU approves Farydak (panobinostat) in combination with bortezomib and dexamethasone to treat refractory multiple myeloma - Novartis

    Novartis announced that the European Commission has approved Farydak (panobinostat, previously known as LBH589) capsules, in combination with bortezomib and...

    Journals
    Journal
    30/04/18

    EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

    This article summarizes the scientific review of the application leading to regulatory approval in the European Union.

    • Source: The Oncologist
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/06/15

    Phase III PANORAMA-1 trial subgroup analysis for Farydak (panobinostat) for multiple myeloma- Novartis

    Novartis has presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/12/15

    NICE now recommends combination Farydak + Velcade (panobinostat + bortezomib+ dexamethasone) to treat multiple myeloma- Novartis

    The National Institute for Health and Care Excellence (NICE) in a final appraisal now recommends Farydak + Velcade (panobinostat +...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/02/15

    Farydak (panobinostat) has FDA accelerated approval to treat multiple myeloma- Novartis

    Novartis announced that the FDA has approved Farydak (panobinostat, previously known as LBH 589) capsules in combination with bortezomib and...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    26/06/15

    CHMP recommends Farydak (panobinostat) to treat multiple myeloma - Novartis

    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    02/06/14

    LBH 589 success in PANORAMA study for Multiple Myeloma - Novartis

    Novartis presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/11/14

    FDA Advisory Committee does not recommend LBH 589 for treatment of Multiple Myeloma - Novartis

    Novartis has announced that the FDA Oncologic Drugs Advisory Committee (ODAC) did not recommend the investigational compound LBH 589 (panobinostat),...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/12/13

    LBH 589 success in Phase III Multiple Myeloma trial-Novartis

    Novartis has announced that results of a Phase III trial of the investigational compound LBH 589 (panobinostat) in combination with...

    Journals
    Journal
    01/10/23

    Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

    Purpose: Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex).

    • Source: Journal of Clinical Oncology
    See more